HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. (14th August 2012)

• Record Type: Journal Article
• Authors: Perisanidis, C; Savarese‐Brenner, B; Würger, T; Wrba, F; Huynh, A; Schopper, C; Kornek, G; Selzer, E; Ewers, R; Psyrri, A; Krainer, M; Filipits, M
• Is Part Of: Oral diseases. Volume 19:Number 2(2013:Mar.)
• Page Start: 206
• Page End: 211
• Publication Date: 2012-08-14
• Subjects: Mouth -- Diseases -- Research -- Periodicals; 617.522
• DOI: 10.1111/j.1601-0825.2012.01972.x
• Languages: English
• ISSNs: 1354-523X

Abstract

<abstract abstract-type="main" id="odi1972-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="odi1972-sec-0001" sec-type="section"> <title>Objective</title> <p>The hepatocellular carcinoma‐related protein 1 (HCRP1) is a key factor in the degradation of the epidermal growth factor receptor. In this study, we assessed the prognostic significance of HCRP1 expression in patients with oral and oropharyngeal squamous cell carcinoma (OOSCC).</p> </sec> <sec id="odi1972-sec-0002" sec-type="section"> <title>Methods</title> <p>HCRP1 expression was determined by immunohistochemistry on tissue biopsy sections of 111 patients with locally advanced OOSCC undergoing neoadjuvant chemoradiotherapy followed by surgery. The Kaplan–Meier method and Cox regression models were used for survival analyses.</p> </sec> <sec id="odi1972-sec-0003" sec-type="section"> <title>Results</title> <p>Low HCRP1 expression was associated with poor recurrence‐free survival (<italic>P </italic>=<italic> </italic>0.046) and overall survival (<italic>P </italic>=<italic> </italic>0.03). Multivariate analysis revealed that low HCRP1 expression remained an independent risk factor for relapse (HR 2.98, 95% CI 1.19–7.49, <italic>P </italic>=<italic> </italic>0.02) and death (HR 3.04, 95% CI 1.19–7.79, <italic>P </italic>=<italic> </italic>0.02).</p> </sec> <sec id="odi1972-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Low HCRP1 expression was found to be of adverse prognostic significance in patients with OOSCC who received preoperative chemoradiotherapy.</p> </sec> </abstract>